Orgenesis stock: MarketBeat estimates November 11 results for Orgenesis stock

Published on 10/28/2026 at 06:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Earnings are estimated for November 11, 2026. Orgenesis stock has consensus revenue of USD 2.80 million and earnings per share of minus USD 2.60.

Earnings calendar and valuation

Orgenesis is estimated to report results on November 11, 2026.
Consensus revenue is USD 2.80 million and consensus earnings per share are minus USD 2.60.
Orgenesis had a market capitalization of USD 2.9 million as of October 28, 2026.

ORGS, US68619K3032, Illustration mit AI erstellt.

Orgenesis (ISIN US68619K3032) is estimated to report its next results on November 11, 2026, with expected revenue of USD 2.80 million and expected earnings per share of minus USD 2.60. MarketBeat identifies the date as an estimate based on past reporting schedules.

November 11 carries the main signal

The scheduled date gives investors a defined checkpoint for the company's next financial update. The same MarketBeat estimate puts revenue at USD 2.80 million and earnings per share at minus USD 2.60, making the forecast operating result the clearest numerical benchmark for the announcement.

The figures are estimates rather than reported results. That distinction matters because the available MarketBeat page describes the date as subject to change until Orgenesis confirms it.

What does the estimate mean?

The expected revenue of USD 2.80 million provides the top-line reference, while earnings per share of minus USD 2.60 points to a projected loss. Investors can therefore compare the eventual release with both the revenue estimate and the per-share forecast.

Platform remains the longer view

Orgenesis describes its business as a cell and gene therapy company built around the POCare platform. Its investor-relations page says the platform combines therapies, technologies and a network of academic, research and hospital partners to support point-of-care development and manufacturing. The company also describes automated processing systems designed for personalized therapies and standardized production.

The company profile supports a focus on biotechnology rather than a diversified healthcare model. That makes the November 11 update important for assessing whether the platform is translating into measurable revenue and whether the projected loss is narrowing or widening.

Dates set the next checkpoint

MarketBeat lists November 11, 2026, as the estimated earnings announcement date. The estimate includes expected revenue of USD 2.80 million and expected earnings per share of minus USD 2.60.

Market value and company profile

Orgenesis had a market capitalization of USD 2.9 million as of October 28, 2026. The finance profile classifies the company in Healthcare and Biotechnology and lists Vered Caplan as chief executive officer. The investor-relations page presents Orgenesis as a global cell and gene therapy business working to lower the cost of personalized treatments.